Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphodiesterase 9 (PDE9) is a phosphodiesterase enzyme that specifically hydrolyzes cyclic GMP (cGMP), playing a crucial role in regulating intracellular cGMP levels in tissues like the heart, brain, and adipose tissue. It is a therapeutic target for conditions such as heart failure, cognitive impairment, and metabolic disorders. Inhibition of PDE9 leads to increased myocardial cGMP levels and has demonstrated potential for reversing/preventing cardiac hypertrophy and dysfunction, improving cognitive function, and enhancing metabolic health.
Selective inhibition of PDE9, leading to increased intracellular cGMP levels.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphodiesterase 9 (PDE9).